UY36688A - Compuestos de imidazotriazina - Google Patents

Compuestos de imidazotriazina

Info

Publication number
UY36688A
UY36688A UY0001036688A UY36688A UY36688A UY 36688 A UY36688 A UY 36688A UY 0001036688 A UY0001036688 A UY 0001036688A UY 36688 A UY36688 A UY 36688A UY 36688 A UY36688 A UY 36688A
Authority
UY
Uruguay
Prior art keywords
compound
leishmaniasis
imidazotriazine compounds
imidazotriazine
compounds
Prior art date
Application number
UY0001036688A
Other languages
English (en)
Inventor
Michael George Thomas
Timothy James Miles
Elisabet Viayna Gaza;
Eun Jung Ko
Gilbert Ian
Maria Marco Martin
Brand Stephen
Lars Henrik Sandberg
Original Assignee
Univ Dundee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee, Glaxosmithkline Ip Dev Ltd filed Critical Univ Dundee
Publication of UY36688A publication Critical patent/UY36688A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de Formula (I), o una de sus sales, composiciones que comprenden el compuesto, procedimientos para su preparación y su uso en terapia, por ejemplo, en el tratamiento de enfermedades parasitarias tales como enfermedad de Chagas, tripanosomiasis africana humana (HAT) y leishmaniasis, particularmente leishmaniasis visceral (VL).
UY0001036688A 2015-05-29 2016-05-27 Compuestos de imidazotriazina UY36688A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382283 2015-05-29

Publications (1)

Publication Number Publication Date
UY36688A true UY36688A (es) 2016-12-30

Family

ID=53398015

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036688A UY36688A (es) 2015-05-29 2016-05-27 Compuestos de imidazotriazina

Country Status (14)

Country Link
US (1) US10065965B2 (es)
EP (1) EP3303336A1 (es)
JP (1) JP2018516265A (es)
CN (1) CN107922419A (es)
AR (1) AR104749A1 (es)
AU (1) AU2016269626B2 (es)
BR (1) BR112017025668A2 (es)
CA (1) CA2987329A1 (es)
CL (1) CL2017003025A1 (es)
CO (1) CO2017011969A2 (es)
CR (1) CR20170546A (es)
TW (1) TW201713661A (es)
UY (1) UY36688A (es)
WO (1) WO2016193111A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127627A1 (en) 2016-01-21 2017-07-27 The University Of North Carolina At Chapel Hill Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
CN108129409B (zh) * 2018-01-22 2020-07-03 三金集团湖南三金制药有限责任公司 一种改进的合成拉莫三嗪的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151799A2 (en) * 2009-06-26 2010-12-29 University Of Massachusetts Compounds for modulating rna binding proteins and uses therefor
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9233961B2 (en) * 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
MA39186A1 (fr) 2013-12-19 2017-11-30 Novartis Ag Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose

Also Published As

Publication number Publication date
AR104749A1 (es) 2017-08-09
US20180141949A1 (en) 2018-05-24
US10065965B2 (en) 2018-09-04
TW201713661A (zh) 2017-04-16
CL2017003025A1 (es) 2018-03-16
CN107922419A (zh) 2018-04-17
AU2016269626B2 (en) 2019-05-30
JP2018516265A (ja) 2018-06-21
CO2017011969A2 (es) 2018-02-09
CR20170546A (es) 2018-04-02
AU2016269626A1 (en) 2017-12-14
CA2987329A1 (en) 2016-12-08
BR112017025668A2 (pt) 2018-08-07
WO2016193111A1 (en) 2016-12-08
EP3303336A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
DOP2016000271A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
ECSP19026702A (es) Compuestos novedosos para el tratamiento de enfermedades parasitarias
CL2016001421A1 (es) Derivados de [1,2,4] triazolo [1,5-a] pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias como la leishmaniasis.
CY1124151T1 (el) Ενωσεις
CL2017003025A1 (es) Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios.
CL2017000040A1 (es) Inhibidores de aldosterona sintasa.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.